Please Wait.....
Report
Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single-Use Equipment), Process (Cell Processing, Preservation), Cell type (T-Cells, Stem cells), End User (Biopharma, CROs, CMOs), Region - Global Forecast to 2028
Market Report I 2023-07-27 I 236 Pages I MarketsandMarkets
The global cell therapy technologies market size is projected to reach USD 7.8 billion by 2028 from USD 4.2 billion in 2023, at a CAGR of 13.3 % during the forecast period. Factors such as increasing government investments in cell-based research, rising incidence of chronic and infectious diseases, large no of oncology related cell therapy clinical trials, increasing GMP certification for cell therapy production facilities are likely to have positive impact on the market growth.
"The process segment held the dominant share in the cell therapy technologies market"
Based on process, the global cell therapy technologies market is segmented into cell processing, cell preservation, distribution & handling, process monitoring & quality control. The cell processing segment held a dominant share in the market in 2022. Advancement in cell processing techniques is likely to have positive impact on the growth of the market.
"Biopharmaceutical and biotechnology companies segment accounted for the largest share of the application segment in 2022."
Based on end users, the cell therapy technologies market is segmented into biopharmaceutical & biotechnology companies, CROS & CMOS, research institutes & cell banks. In 2022, the biopharmaceutical and biotechnology companies segment accounted for the largest share of the cell therapy technologies market. The segment held the dominant share in the market owing to various factors such as the emphasis on increase in number of cell therapy manufacturing facilities by key market players and rising investment in research activities of cell therapy.
"Asia Pacific region is likely to grow at a faster pace."
The cell therapy technologies market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by the increasing government investments in cell-based research. The increasing demand for cell therapy instruments and products from China, India, and Japan due to the rising research funding for vaccine development and changing disease profiles supports market growth in the Asia Pacific. Furthermore, increasing incidence of chronic and infectious diseases, the rising geriatric population, and government initiatives for healthcare infrastructural improvements are some of the elements anticipated to account for positive impact on the market growth.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70%, and Demand Side - 30%
- By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc. (US)
- Merck KGaA (Germany)
- Danaher Corporation (US)
- Lonza Group (Switzerland)
- Sartorius AG(Germany)
- Terumo Bct, Inc Corporation (Japan) (Terumo BCT is part of Terumo Corporation)
- Becton, Dickinson & Company (US)
- Fresenius Se & co. KGaA (Germany)
- Avantor Inc (US)
- Bio-Techne (US)
- Corning Incorporated (US)
- Fujifilm Irvine Scientific (Japan)
- Maxcyte Inc. (US)
- Werum Software & Systems AG (Part of Korber AG) (Germany)
- Roosterbio Inc. (US)
- Sirion Biotech Gmbh (Germany)
- Trakcel (UK)
- L 7 Informatics Inc. (US)
- Miltenyi Biotech (Germany)
- Steamcell Technologies Inc. (Canada)
- GPI Iberia (Formerly Hemasoft) (Spain)
- CodexThemes (France)
- Organabio LLC. (US)
- Ixcells Biotechnologies (US)
- Wilson Wolf 2019 Manufacturing Corporation (US)
Research Coverage:
This report provides a detailed picture of the cell therapy technologies market. It aims at estimating the size and future growth potential of the market across different segments, such as product, process,cell type, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing government investments in cell-based research, Rising incidence of chronic and infectious diseases, large no of oncology related cell therapy clinical trials, Increasing GMP certification for cell therapy production facilities), restraints ( High cost of cell-based research and low success rate), opportunities (Emergence of iPSC as alternatives to ESCs, Increased focus on personalized medicine, Increasing public-private partnerships for development of cell therapies, Emerging Asian markets), and challenges (Survival for small players and new entrants)are influencing the growth of cell therapy technologies market.
- Product Development/Innovation: Detailed insights on newly launched products of the cell therapy technologies market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the Cell therapy technologies market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the cell therapy technologies market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Becton, Dickinson, and Company (US), Lonza Group (Switzerland), Sartorius AG (Germany), and among others in the cell therapy technologies market.
1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.2.1 INCLUSIONS AND EXCLUSIONS 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
1.3.2 YEARS CONSIDERED 34
1.3.3 CURRENCY CONSIDERED 35
1.4 RESEARCH LIMITATIONS 35
1.5 STAKEHOLDERS 35
1.6 SUMMARY OF CHANGES 36
1.7 RECESSION IMPACT 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
FIGURE 1 RESEARCH DESIGN 37
2.1.1 SECONDARY DATA 38
2.1.2 PRIMARY DATA 39
FIGURE 2 CELL THERAPY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARIES 39
2.2 MARKET SIZE ESTIMATION 40
FIGURE 3 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022 40
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 41
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022 41
2.2.1 INSIGHTS FROM PRIMARIES 43
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 43
2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, PROCESS, CELL TYPE, AND END USER) 43
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 43
2.3 GROWTH RATE ASSUMPTIONS 44
FIGURE 8 CELL THERAPY TECHNOLOGIES MARKET: CAGR PROJECTIONS, 2023-2028 45
FIGURE 9 CELL THERAPY TECHNOLOGIES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 45
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 46
FIGURE 10 DATA TRIANGULATION METHODOLOGY 46
2.5 STUDY ASSUMPTIONS 47
2.6 RISK ANALYSIS 47
2.7 RECESSION IMPACT ANALYSIS 47
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024-2028 (% GROWTH) 48
TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION) 48
TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION) 48
3 EXECUTIVE SUMMARY 49
FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 49
FIGURE 12 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION) 50
FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023 VS. 2028 (USD MILLION) 50
FIGURE 14 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 51
FIGURE 15 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC SNAPSHOT 52
4 PREMIUM INSIGHTS 53
4.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW 53
FIGURE 16 INCREASING GOVERNMENT INVESTMENT IN CELL-BASED RESEARCH TO BOOST ADOPTION OF CELL THERAPY TECHNOLOGIES 53
4.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT AND COUNTRY (2022) 54
FIGURE 17 T CELLS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 54
4.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2023 VS. 2028 54
FIGURE 18 MEDIA, SERA, AND REAGENTS SEGMENT TO DOMINATE MARKET IN 2028 54
4.4 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY END USER, 2022 (USD MILLION) 55
FIGURE 19 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES DOMINATED MARKET IN 2022 55
4.5 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 55
FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
FIGURE 21 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
5.2.1 DRIVERS 57
5.2.1.1 Increasing government investments in cell-based research 57
TABLE 4 NIH FUNDING FOR CELL-BASED RESEARCH, 2019-2022 (USD MILLION) 57
5.2.1.2 Rising incidence of chronic and infectious diseases 58
5.2.1.3 Large number of oncology-related cell therapy clinical trials 58
FIGURE 22 CANCER CELL THERAPY PIPELINE, 2021-2022 59
5.2.1.4 Increasing GMP certifications for cell therapy production facilities 59
TABLE 5 EXAMPLES OF MANUFACTURING CERTIFICATIONS AND APPROVALS FOR GMP 59
5.2.2 RESTRAINTS 60
5.2.2.1 High cost of cell-based research and low success rate 60
TABLE 6 COST OF CELL THERAPY EQUIPMENT 60
5.2.3 OPPORTUNITIES 60
5.2.3.1 Emergence of iPSCs as alternatives to ESCs 60
5.2.3.2 Increased focus on personalized medicine 61
5.2.3.3 Increasing partnerships for development of cell therapies 61
5.2.3.4 Emerging Asian markets 62
5.2.4 CHALLENGES 63
5.2.4.1 Survival of small players and new entrants 63
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 63
FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR CELL THERAPY TECHNOLOGIES PROVIDERS 63
5.4 INDICATIVE PRICING MODEL ANALYSIS 63
TABLE 7 PRICING ANALYSIS OF CELL THERAPY PRODUCTS 63
5.5 TECHNOLOGY ANALYSIS 64
5.6 VALUE CHAIN ANALYSIS 64
FIGURE 24 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE 65
5.7 SUPPLY CHAIN ANALYSIS 65
FIGURE 25 CELL THERAPY TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS 66
5.8 ECOSYSTEM ANALYSIS OF CELL THERAPY TECHNOLOGIES MARKET 67
FIGURE 26 ECOSYSTEM ANALYSIS 67
TABLE 8 SUPPLY CHAIN ECOSYSTEM 67
5.9 KEY CONFERENCES AND EVENTS IN 2022-2023 68
TABLE 9 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 68
5.10 REGULATORY ANALYSIS 69
5.10.1 REGULATORY LANDSCAPE FOR CELL THERAPIES 69
TABLE 10 NORTH AMERICA: REGULATORY LANDSCAPE FOR CELL THERAPIES 69
TABLE 11 EUROPE: REGULATORY LANDSCAPE FOR CELL THERAPIES 70
TABLE 12 ASIA PACIFIC: REGULATORY LANDSCAPE FOR CELL THERAPIES 70
TABLE 13 ROW: REGULATORY LANDSCAPE FOR CELL THERAPIES 72
5.10.2 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
5.11 PORTER'S FIVE FORCES ANALYSIS 76
TABLE 19 CELL THERAPY TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS 76
5.11.1 THREAT OF NEW ENTRANTS 76
5.11.2 THREAT OF SUBSTITUTES 76
5.11.3 BARGAINING POWER OF SUPPLIERS 76
5.11.4 BARGAINING POWER OF BUYERS 76
5.11.5 DEGREE OF COMPETITION 76
5.12 PATENT ANALYSIS 77
FIGURE 27 PATENT APPLICATIONS FOR CELL THERAPY TECHNOLOGIES, JULY 2013-JULY 2023 77
TABLE 20 CELL THERAPY TECHNOLOGIES MARKET: INDICATIVE LIST OF PATENTS 78
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 79
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CELL THERAPY PRODUCTS 79
5.13.2 BUYING CRITERIA FOR CELL THERAPY PRODUCTS 80
FIGURE 29 KEY BUYING CRITERIA FOR END USERS 80
6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT 81
6.1 INTRODUCTION 82
TABLE 21 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 82
6.2 MEDIA, SERA, AND REAGENTS 82
6.2.1 IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET 82
TABLE 22 MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION) 83
TABLE 23 NORTH AMERICA: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 83
TABLE 24 EUROPE: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 84
TABLE 25 ASIA PACIFIC: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 84
6.3 CELL ENGINEERING PRODUCTS 85
6.3.1 AVAILABILITY OF VARIOUS CELL ENGINEERING PRODUCTS TO SUPPORT MARKET GROWTH 85
TABLE 26 CELL ENGINEERING PRODUCTS OFFERED, BY COMPANY 85
TABLE 27 CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION) 85
TABLE 28 NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 86
TABLE 29 EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 86
TABLE 30 ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 86
6.4 CELL CULTURE VESSELS 87
6.4.1 WIDE USAGE OF CELL CULTURE VESSELS IN CELL GROWTH APPLICATIONS 87
TABLE 31 CELL CULTURE VESSELS MARKET, BY REGION, 2021-2028 (USD MILLION) 87
TABLE 32 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 87
TABLE 33 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 88
TABLE 34 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 88
6.5 CELL THERAPY EQUIPMENT 88
TABLE 35 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 89
TABLE 36 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION) 89
TABLE 37 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, 2021-2028 (USD MILLION) 90
TABLE 38 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 90
TABLE 39 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 90
6.5.1 CELL PROCESSING EQUIPMENT 91
6.5.1.1 Cell processing equipment to dominate market 91
TABLE 40 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION) 91
TABLE 41 NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 92
TABLE 42 EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 92
TABLE 43 ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 92
6.5.2 SINGLE-USE EQUIPMENT 93
6.5.2.1 Benefits of single-use equipment to ensure end-user demand 93
TABLE 44 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION) 93
TABLE 45 NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 93
TABLE 46 EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 94
TABLE 47 ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 94
6.5.3 OTHER EQUIPMENT 94
TABLE 48 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION) 95
TABLE 49 NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 95
TABLE 50 EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 95
TABLE 51 ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 96
6.6 SYSTEMS & SOFTWARE 96
6.6.1 NEED TO MONITOR DIFFERENT STAGES OF CELL PROCESSING TO DRIVE DEMAND 96
TABLE 52 SYSTEMS & SOFTWARE MARKET, BY REGION, 2021-2028 (USD MILLION) 97
TABLE 53 NORTH AMERICA: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 97
TABLE 54 EUROPE: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 97
TABLE 55 ASIA PACIFIC: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 98
6.7 OTHER PRODUCTS 98
TABLE 56 OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION) 98
TABLE 57 NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 99
TABLE 58 EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 99
TABLE 59 ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 99
7 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS 100
7.1 INTRODUCTION 101
TABLE 60 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 101
7.2 CELL PROCESSING 101
7.2.1 CELL PROCESSING TO HOLD LARGEST MARKET SHARE TILL 2028 101
TABLE 61 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2021-2028 (USD MILLION) 102
TABLE 62 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION) 102
TABLE 63 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION) 103
TABLE 64 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION) 103
7.3 CELL PRESERVATION, DISTRIBUTION, AND HANDLING 103
7.3.1 INCREASING DEMAND FOR CELL-BASED MEDICAL PRODUCTS AND THERAPIES TO DRIVE SEGMENT GROWTH 103
TABLE 65 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2021-2028 (USD MILLION) 104
TABLE 66 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021-2028 (USD MILLION) 104
TABLE 67 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021-2028 (USD MILLION) 105
TABLE 68 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021-2028 (USD MILLION) 105
7.4 PROCESS MONITORING & QUALITY CONTROL 105
7.4.1 NEED TO ENSURE QUALITY AND ACCURACY OF CELL PROCESSING TO BOOST ADOPTION 105
TABLE 69 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY REGION, 2021-2028 (USD MILLION) 106
TABLE 70 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION) 106
TABLE 71 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION) 107
TABLE 72 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION) 107
8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE 108
8.1 INTRODUCTION 109
TABLE 73 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 109
8.2 T CELLS 109
8.2.1 RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH 109
TABLE 74 CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY REGION, 2021-2028 (USD MILLION) 110
TABLE 75 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021-2028 (USD MILLION) 110
TABLE 76 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021-2028 (USD MILLION) 111
TABLE 77 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021-2028 (USD MILLION) 111
8.3 STEM CELLS 112
8.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET 112
TABLE 78 CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY REGION, 2021-2028 (USD MILLION) 112
TABLE 79 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021-2028 (USD MILLION) 113
TABLE 80 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021-2028 (USD MILLION) 113
TABLE 81 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021-2028 (USD MILLION) 113
8.4 OTHER CELLS 114
TABLE 82 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY REGION, 2021-2028 (USD MILLION) 114
TABLE 83 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021-2028 (USD MILLION) 114
TABLE 84 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021-2028 (USD MILLION) 115
TABLE 85 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021-2028 (USD MILLION) 115
?
9 CELL THERAPY TECHNOLOGIES MARKET, BY END USER 116
9.1 INTRODUCTION 117
TABLE 86 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 117
9.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 117
9.2.1 GROWING NUMBER OF CELL THERAPY MANUFACTURING FACILITIES TO DRIVE MARKET 117
TABLE 87 CELL THERAPY TECHNOLOGIES MARKET & BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION) 118
TABLE 88 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) 118
TABLE 89 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) 119
TABLE 90 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) 119
9.3 CROS & CMOS 119
9.3.1 FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH 119
TABLE 91 CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2021-2028 (USD MILLION) 120
TABLE 92 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021-2028 (USD MILLION) 120
TABLE 93 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021-2028 (USD MILLION) 121
TABLE 94 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021-2028 (USD MILLION) 121
9.4 RESEARCH INSTITUTES & CELL BANKS 121
9.4.1 RISING RESEARCH ACTIVITY TO SUPPORT MARKET GROWTH 121
TABLE 95 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY REGION, 2021-2028 (USD MILLION) 122
TABLE 96 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021-2028 (USD MILLION) 122
TABLE 97 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021-2028 (USD MILLION) 123
TABLE 98 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021-2028 (USD MILLION) 123
10 CELL THERAPY TECHNOLOGIES MARKET, BY REGION 124
10.1 INTRODUCTION 125
TABLE 99 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2021-2028 (USD MILLION) 125
10.2 NORTH AMERICA 125
10.2.1 NORTH AMERICA: RECESSION IMPACT 125
FIGURE 30 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT 126
TABLE 100 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 127
TABLE 101 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 127
TABLE 102 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 127
TABLE 103 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 128
TABLE 104 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 128
TABLE 105 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 128
10.2.2 US 129
10.2.2.1 Increasing R&D activities to support market growth 129
TABLE 106 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 129
TABLE 107 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 129
TABLE 108 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 130
TABLE 109 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 130
TABLE 110 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 130
10.2.3 CANADA 131
10.2.3.1 Increasing government funding to drive adoption of cell therapy instruments 131
TABLE 111 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 131
TABLE 112 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 132
TABLE 113 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 132
TABLE 114 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 132
TABLE 115 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 133
10.3 EUROPE 133
10.3.1 EUROPE: RECESSION IMPACT 133
TABLE 116 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 134
TABLE 117 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 134
TABLE 118 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 135
TABLE 119 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 135
TABLE 120 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 135
TABLE 121 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 136
10.3.2 GERMANY 136
10.3.2.1 Germany to hold largest share of European market 136
TABLE 122 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 137
TABLE 123 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 137
TABLE 124 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 138
TABLE 125 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 138
TABLE 126 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 138
10.3.3 UK 139
10.3.3.1 Favorable funding and investment scenario to drive market 139
TABLE 127 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 139
TABLE 128 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 139
TABLE 129 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 140
TABLE 130 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 140
TABLE 131 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 140
10.3.4 FRANCE 141
10.3.4.1 Availability of government and private support to drive market 141
TABLE 132 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 141
TABLE 133 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 141
TABLE 134 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 142
TABLE 135 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 142
TABLE 136 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 142
10.3.5 ITALY 143
10.3.5.1 Initiatives favoring cell and gene therapy development to support market growth 143
TABLE 137 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 143
TABLE 138 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 143
TABLE 139 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 144
TABLE 140 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 144
TABLE 141 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 144
10.3.6 SPAIN 145
10.3.6.1 Increasing funding from private and public organizations to aid market growth 145
TABLE 142 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 145
TABLE 143 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 145
TABLE 144 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 146
TABLE 145 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 146
TABLE 146 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 146
10.3.7 REST OF EUROPE 147
TABLE 147 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 147
TABLE 148 REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 147
TABLE 149 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 148
TABLE 150 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 148
TABLE 151 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 148
10.4 ASIA PACIFIC 149
FIGURE 31 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT 149
10.4.1 ASIA PACIFIC: RECESSION IMPACT 150
TABLE 152 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 150
TABLE 153 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 151
TABLE 154 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 151
TABLE 155 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 152
TABLE 156 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 152
TABLE 157 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 152
10.4.2 CHINA 153
10.4.2.1 Increasing cell therapy-based trials to support market growth 153
TABLE 158 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 153
TABLE 159 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 154
TABLE 160 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 154
TABLE 161 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 154
TABLE 162 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 155
10.4.3 JAPAN 155
10.4.3.1 Rising geriatric population and growing disease prevalence to drive market 155
TABLE 163 JAPAN: CANCER INCIDENCE IN MALES VS FEMALES, BY TYPE, 2022 156
TABLE 164 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 156
TABLE 165 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 157
TABLE 166 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 157
TABLE 167 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 157
TABLE 168 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 158
10.4.4 INDIA 158
10.4.4.1 Favorable government regulations to support market growth 158
TABLE 169 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 159
TABLE 170 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 159
TABLE 171 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 160
TABLE 172 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 160
TABLE 173 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 160
10.4.5 REST OF ASIA PACIFIC 161
TABLE 174 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 161
TABLE 175 REST OF ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 161
TABLE 176 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 162
TABLE 177 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 162
TABLE 178 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 162
10.5 LATIN AMERICA 163
10.5.1 AVAILABILITY OF GRANTS FOR CELL-BASED RESEARCH TO DRIVE MARKET 163
10.5.2 LATIN AMERICA: RECESSION IMPACT 163
TABLE 179 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 164
TABLE 180 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 164
TABLE 181 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 165
TABLE 182 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 165
TABLE 183 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 165
10.6 MIDDLE EAST & AFRICA 166
10.6.1 INCREASING R&D FUNDING FOR STEM CELL THERAPY TO DRIVE MARKET 166
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 166
TABLE 184 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 167
TABLE 185 MIDDLE EAST & AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 167
TABLE 186 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 168
TABLE 187 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 168
TABLE 188 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 168
11 COMPETITIVE LANDSCAPE 169
11.1 INTRODUCTION 169
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 170
FIGURE 32 CELL THERAPY TECHNOLOGIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 170
11.3 REVENUE SHARE ANALYSIS 171
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2020-2022 171
11.4 MARKET SHARE ANALYSIS 171
FIGURE 34 CELL THERAPY TECHNOLOGIES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022 172
TABLE 189 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION 172
11.5 COMPANY EVALUATION MATRIX, 2022 173
11.5.1 STARS 174
11.5.2 EMERGING LEADERS 174
11.5.3 PERVASIVE PLAYERS 174
11.5.4 PARTICIPANTS 174
FIGURE 35 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 175
11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 176
11.6.1 COMPANY PRODUCT FOOTPRINT (25 COMPANIES) 176
TABLE 190 PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS 176
11.6.2 COMPANY PROCESS FOOTPRINT (25 COMPANIES) 177
TABLE 191 PROCESS FOOTPRINT ANALYSIS: KEY PLAYERS 177
11.6.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES) 178
TABLE 192 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS 178
11.7 COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 179
11.7.1 PROGRESSIVE COMPANIES 179
11.7.2 STARTING BLOCKS 179
11.7.3 RESPONSIVE COMPANIES 179
11.7.4 DYNAMIC COMPANIES 179
FIGURE 36 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 180
11.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 181
TABLE 193 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS 181
TABLE 194 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS 182
11.9 COMPETITIVE SCENARIO AND TRENDS 183
11.9.1 PRODUCT LAUNCHES 183
TABLE 195 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2020-APRIL 2023 183
11.9.2 DEALS 184
TABLE 196 CELL THERAPY TECHNOLOGIES MARKET: DEALS, JANUARY 2020-APRIL 2023 184
11.9.3 OTHER DEVELOPMENTS 185
TABLE 197 CELL THERAPY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS, JANUARY 2020-APRIL 2023 185
12 COMPANY PROFILES 186
12.1 KEY MARKET PLAYERS 186
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 THERMO FISHER SCIENTIFIC, INC. 186
TABLE 198 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 186
FIGURE 37 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 187
12.1.2 MERCK KGAA 191
TABLE 199 MERCK KGAA: BUSINESS OVERVIEW 191
FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2022) 192
12.1.3 DANAHER CORPORATION 195
TABLE 200 DANAHER CORPORATION: BUSINESS OVERVIEW 195
FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 196
12.1.4 LONZA GROUP 200
TABLE 201 LONZA GROUP: BUSINESS OVERVIEW 200
FIGURE 40 LONZA GROUP: COMPANY SNAPSHOT (2022) 201
12.1.5 SARTORIUS AG 203
TABLE 202 SARTORIUS AG: BUSINESS OVERVIEW 203
FIGURE 41 SARTORIUS AG: COMPANY SNAPSHOT (2022) 204
12.1.6 TERUMO BCT, INC. 206
TABLE 203 TERUMO BCT, INC: BUSINESS OVERVIEW 206
FIGURE 42 TERUMO BCT, INC.: COMPANY SNAPSHOT (2022) 207
12.1.7 BECTON DICKINSON AND COMPANY 209
TABLE 204 BECTON DICKINSON AND COMPANY: BUSINESS OVERVIEW 209
FIGURE 43 BECTON DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 210
12.1.8 FRESENIUS SE & CO. KGAA 212
TABLE 205 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW 212
FIGURE 44 FRESENIUS SE & CO: COMPANY SNAPSHOT (2022) 213
12.1.9 AVANTOR, INC. 215
TABLE 206 AVANTOR, INC.: BUSINESS OVERVIEW 215
FIGURE 45 AVANTOR, INC.: COMPANY SNAPSHOT (2022) 215
12.1.10 BIO-TECHNE 218
TABLE 207 BIO-TECHNE: BUSINESS OVERVIEW 218
FIGURE 46 BIO-TECHNE: COMPANY SNAPSHOT (2022) 219
12.1.11 CORNING INCORPORATED 221
TABLE 208 CORNING INCORPORATED: BUSINESS OVERVIEW 221
FIGURE 47 CORNING INCORPORATED: COMPANY SNAPSHOT (2022) 222
12.1.12 FUJIFILM IRVINE SCIENTIFIC 223
TABLE 209 FUJIFILM IRVINE SCIENTIFIC: BUSINESS OVERVIEW 223
FIGURE 48 FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT (2022) 224
12.1.13 MAXCYTE, INC. 226
TABLE 210 MAXCYTE, INC.: BUSINESS OVERVIEW 226
FIGURE 49 MAXCYTE, INC.: COMPANY SNAPSHOT (2022) 226
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 228
12.2.1 WERUM IT SOLUTIONS 228
12.2.2 ROOSTERBIO, INC. 229
12.2.3 SIRION BIOTECH 230
12.2.4 TRAKCEL 230
12.2.5 L7 INFORMATICS, INC. 231
12.2.6 MILTENYI BIOTEC B.V. & CO. KG 231
12.2.7 STEMCELL TECHNOLOGIES 233
12.2.8 GPI IBERIA (FORMERLY HEMASOFT) 234
12.2.9 MAK-SYSTEM 235
12.2.10 ORGANABIO 235
12.2.11 IXCELLS BIOTECHNOLOGIES 236
12.2.12 WILSON WOLF 236
?
13 APPENDIX 237
13.1 DISCUSSION GUIDE 237
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 241
13.3 CUSTOMIZATION OPTIONS 243
13.4 RELATED REPORTS 243
13.5 AUTHOR DETAILS 244
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security